Objective: To investigate the hemodynamic profile associated with different target temperatures and to assess the prognostic implication of inotropic/vasopressor support and mean arterial pressure after out-of-hospital cardiac arrest. There is a lack of information how different target temperatures may affect hemodynamics. Design: Post hoc analysis of a prospective randomized study. Setting: Thirthy-six ICUs in 10 countries. Patients: Nine hundred twenty patients (97%) with available vasopressor data out of 950 patients from the Target Temperature Management trial randomly assigned patients to a targeted temperature management at 33°C or 36°C. Interventions: None. Measurements and Main Results: Mean arterial pressure, heart rate, and lactate were registered at prespecified time points. The population was stratified according to cardiovascular Sequential Organ Failure Assessment = 4 defining the high vasopressor group and cardiovascular Sequential Organ Failure Assessment less than or equal to 3 defining the low vasopressor group. The targeted temperature management 33 (TTM33) group had a hemodynamic profile with lower heart rate (-7.0 min -1 [95% confidence limit, -8.7, -5.1]; p group < 0.0001), similar mean arterial pressure (-1.1 mm Hg [95% confidence limit, -2.3, 0.2]; p group = 0.10), and increased lactate (0.6 mmol/L [95% confidence limit, 0.3, 0.8];
p group < 0.0001) compared with the targeted temperature management 36 (TTM36) group. A cardiovascular Sequential Organ Failure Assessment score = 4 was recorded in 54% versus 45%, p = 0.03 in the TTM33 and the TTM36 group, respectively. The high vasopressor group carried a 53% mortality rate when compared with a 34% in the low vasopressor group, p log-rank less than 0.0001, with an adjusted hazard ratio of 1.38 (95% CI, 1.11-1.71; p = 0.004). There was no interaction between vasopressor group and allocated target temperature group (p = 0.40). An inverse relationship between mean arterial pressure and mortality was identified (p = 0.0008). Conclusions: Targeted temperature management at 33°C was associated with hemodynamic alterations with decreased heart rate, elevated levels of lactate, and need for increased vasopressor support compared with targeted temperature management at 36°C. Low mean arterial pressure and need for high doses of vasopressors were associated with increased mortality independent of allocated targeted temperature management. (Crit Care Med 2015; 43:318-327) Key Words: cardiac arrest; hemodynamics; hypothermia; mortality; vasopressor T argeted temperature management (TTM) is an established component of post-cardiac arrest care in unconscious survivors of out-of-hospital cardiac arrest (OHCA). Hemodynamic instability is frequently observed after OHCA as part of a post-cardiac arrest syndrome (PCAS) with clinical and biological manifestations secondary to global ischemia-reperfusion injury (1, 2) . Inducing and maintaining hypothermia after cardiac arrest have a significant impact on central hemodynamics because both cardiac index and heart rate (HR) decrease and the need for vasopressors is increased (3, 4) . Hypotension in the early phase of PCAS has been associated with increased in-hospital mortality previously, but studies suggest that induction of hypothermia does not further compromise hemodynamics (5, 6) . However, the hemodynamic impact of TTM and use of vasopressors extends beyond the induction phase of TTM (7) .
Severity of PCAS is increasingly recognized as an important determinant of outcome and thus strategies to limit PCASrelated injury may potentially improve outcome. A recent large randomized study, the Target Temperature Management after Cardiac arrest trial (TTM trial) compared the beneficial effects of a target temperature of 33°C compared with 36°C after OHCA. Both regimens were equally efficacious in terms of mortality (50% vs 48%; p = 0.51) and unfavorable neurological outcome (54% vs 52%; p = 0.78) (8) . Whether different target temperatures may interfere with the severity of PCAS is unknown. The Sequential Organ Failure Assessment (SOFA) score reflects the severity of organ dysfunction and has been used in previous studies to assess the severity of PCAS (9) (10) (11) (12) .
In the population from the TTM trial, we aimed to investigate the influence of level of TTM on the need for vasopressor/ inotropic support and the differences in hemodynamic profiles.
We hypothesized that the need for higher levels of vasopressor/ inotropic support, as estimated by the cardiovascular SOFA score, is associated with worse outcome. Furthermore, we aimed to investigate the prognostic importance of mean arterial pressure (MAP) during TTM.
MATERIALS AND METHODS

Study Design
The present study is a post hoc analysis of the investigator-initiated, multicenter, randomized, parallel-group, and assessorblinded clinical TTM trial (8) . The design of the present study was approved by the Steering group before end of the main trial. The TTM trial included adult patients (≥ 18 yr) resuscitated from OHCA of presumed cardiac cause, who remained unconscious (Glasgow Coma Scale < 8) after sustained return of spontaneous circulation (ROSC) > 20 minutes. Patients were randomized in a 1:1 ratio to a TTM at 33°C (TTM33) or 36°C (TTM36) for 24 hours after cardiac arrest (8) .
Main exclusion criteria included unwitnessed asystole as primary rhythm and a severe shock state at time of screening defined as sustained systolic blood pressure less than 80 mm Hg despite administration of fluids, vasopressors, inotropes, and/or treatment with intra-aortic balloon pump or left ventricular assist device (13) .
Prehospital data regarding the cardiac arrest were systematically collected at admission according to Utstein guidelines (14) . The trial was approved by ethics committees in each participating country; informed consent was obtained or waived according to national regulations, and guidelines for Good Clinical Practice were followed up and monitored (8) .
Post-cardiac Arrest Care
All patients were admitted to an ICU and were sedated, intubated, and mechanically ventilated throughout the intervention period according to the study protocol (13) . Active cooling was initiated immediately after randomization with a period to achieve target temperature (4 hr), maintenance of target temperature (24 hr) with subsequent active rewarming of no more than 0.5°C/hr to 37°C in both groups (8 hr). After 36 hours, sedation was discontinued and the patients were allowed to recover spontaneously (13) .
Patients hemodynamics were monitored with an arterial pressure catheter and a central venous catheter. Management of the hemodynamics and metabolic parameters was performed at the discretion of the treating physicians at each study site with no prespecified treatment goals for MAP, HR, or urine output because of the pragmatic study design (8) .
Hemodynamic Variables
Data regarding initial temperature and first blood gas analysis including lactate was obtained at ICU admission. The hemodynamic profile in the two TTM groups with HR, MAP, central venous oxygen saturation (Scvo 2 ) and lactate was registered at specific time points throughout the intervention period (0, 4, 12, 20, 28, 32, and 36 hr after randomization). Data regarding serial measurements of Scvo 2 were available in 407 patients. During ICU treatment, the maximum dose of vasopressor/ inotropic support was assessed daily by the cardiovascular subscore of SOFA (12) . Per protocol, the second day started at a prespecified time point for each site meaning that day 1 had variable length (12.2 vs 12.3 hr, not significant, in the two TTM groups). For the present analysis, SOFA scores, urine output, and fluid balance from the first 2 days were used, comprising the intervention period of approximately 36 hours.
Need for vasopressor/inotropic support during the 36-hour intervention period was defined by maximum cardiovascular SOFA score recorded, and the population was stratified by a cardiovascular SOFA score = 4 defining the high vasopressor group and a cardiovascular SOFA score less than or equal to 3 defining the low vasopressor group as suggested by a recent study (7) . Organ dysfunction (sub-SOFA ≥ 3) was defined as the highest sub-SOFA obtained during the 36-hour intervention. MAP was recorded during the intervention at prespecified time points, and the mean of recorded MAP values during intervention was used for multivariable modeling.
Survival status at 30 and 180 days was obtained from the TTM database by the study end date in July 2013. Neurological outcome was assessed with Cerebral Performance Category (CPC) and modified Rankin Scale (15, 16) .
Statistical Analysis
Differences in baseline demographic and hemodynamics variables were compared using Student t test, chi-square test, and Wilcoxon rank sum test, as appropriate. Logistic regression analysis was used in the analysis of factors associated with need for high dose of vasopressor support, as defined by SOFA score = 4. All variables with significant results in univariate analysis were included in multivariate analysis, followed by a stepwise backward elimination. Between TTM group differences during intervention for continuous variables such as MAP, HR, and lactate were analyzed by repeated-measures mixed models with an unstructured covariance structure with TTM group and time point as fixed effects with overall differences reported as β-coefficients and p values denoted p group . Differences and estimates at each time point were assessed by a repeated-measures mixed model including the interaction term of TTM group with time. Mortality analysis between TTM groups and vasopressor groups was assessed by KaplanMeier method and calculated with the log-rank test. The influence of vasopressor support on mortality was assessed by stepwise multivariable Cox modeling after checking for underlying assumptions of linearity, proportionality, and lack of interactions. Cardiovascular SOFA-score and MAP were modeled in the same model to adjust for the confounding effects of the variables, and assessment of interaction was therefore not performed. For illustration of the relation of hazard ratio and level of MAP, an additive multivariable proportional hazard model with smoothing splines was fitted. A two-sided p value of less than 0.05 was considered statistically significant. All statistical analyses were performed using the SAS statistical software, version 9.2 (SAS Institute, Cary, NC) and R Core Team (R: A language and environment for statistical computing, 2013, R Foundation for Statistical Computing, Vienna, Austria; http://www.R-project.org/).
RESULTS
A total of 920 patients were included in the analysis, with 456 patients in the high vasopressor group and 464 patients in the low vasopressor group (Fig. 1) . Patients in the high vasopressor group were older (66 ± 12 vs 62 ± 13 yr; p < 0.0001), time to ROSC was longer (29 min min vs 24 min [15-34] min; p < 0.0001), fewer had bystander cardiopulmonary resuscitation (67% vs 79%; p < 0.0001) and shockable rhythm (76% vs 85%; p = 0.0003) when compared with the low vasopressor group ( Table 1) . Variables associated with the high vasopressor group are shown in Table 2 . , p = 0.46 and lactate levels (4.6 ± 3.8 vs 4.4 ± 3.6 mmol/L; p = 0.48) in the TTM33 group when compared with TTM36 group, respectively. Baseline hemodynamic and metabolic characteristics in the two vasopressor groups are shown in Table 3 .
Hemodynamic Profile During TTM
During the 36-hour intervention period, there was no overall difference in MAP (β = -1.1 mm Hg [95% confidence limit, -2.3, 0.2 mm Hg]; p group = 0.10) in the TTM33 group when compared with the TTM36 group. However, from start of rewarming and during the rewarming phase, MAP was significantly lower in the TTM33 group when compared with that in the TTM36 group with an estimated difference of β = -3.5 mm Hg, (95% confidence limit, -5.0, -2.1 mm Hg; p group < 0.0001) (Fig. 2) . Cardiovascular SOFA score = 4 was recorded in 54% versus 45%, p = 0.03 in the TTM33 versus the TTM36 group, whereas 9% vs 14%, p = 0.03 of patients in the TTM33 versus the TTM36 group did not receive any inotropic/vasopressor therapy, respectively. HR was significantly lower in the TTM33 group when compared with that in the TTM36 during the 36-hour intervention period (β = -7.0 minute -1 [95% confidence limit, -8.7, -5.1 minute -1 ]; p group < 0.0001) (Fig. 2) . There was no overall difference in Scvo 2 (β = 0.2 [95% confidence limit, -0.9, 1.2]; p group = 0.75) or differences in Scvo 2 at any time points between the TTM33 group and the TTM36 group. Furthermore, Scvo 2 was not different between vasopressor groups (p = 0.78), and no interaction between temperature allocation and vasopressor group was found (p = 0.23). Lactate levels remained elevated in the TTM33 group throughout the cooling and rewarming phase (β = 0.6 mmol/L [95% confidence limit, 0.3, 0.8 mmol/L]; p group < 0.0001) (Fig. 2) . Glucose levels were not statistically different between TTM groups (β = 0.2 [95% confidence limit, -0.1, 0.4]; p = 0.22); however, need for high doses of vasopressors (β = 0.3; p < 0.0001) and high lactate (β = 0.6; p < 0.0001) were both associated with higher levels of glucose in the same multivariable model. 
Mortality
Overall 30-day all-cause mortality was 43% in all patients. Patients in the high vasopressor group carried a 53% 30-day mortality rate when compared with 34% in the low vasopressor group, p log-rank < 0.0001. The hazard ratio for 30-day mortality in patients with need for high vasopressor doses during the intervention period was 1.38 (95% CI, 1.11-1.71; p=0.004) in a multivariable model adjusting for TTM group, demographics, prehospital factors, and comorbidities ( Table 4) . Mortality rates stratified by vasopressor group and TTM group were 54% versus 34% in the TTM33 group when compared with 51% versus 35% in the TTM36 group with no difference between vasopressor groups, p interaction = 0.40 (Fig. 3) .
In a multivariable model (adjusting for TTM group, sex, age, rhythm, witnessed arrest, bystander cardiopulmonary resuscitation, time to ROSC, vasopressor group, and initial levels of lactate), mean MAP during intervention was an independent predictor of 30-days mortality (HR = 0.90 [95% CI, 0.85-0.95] per 5 mm Hg increase; p = 0.0008). A fitted smoothing spline plot from a multivariable Cox model with mean MAP during intervention is shown in Figure 4 , and suggested that MAP below 65 mm Hg was associated with increased mortality.
Mortality at 180 days was 57% when compared with 38% in the high and low vasopressor group, p log-rank < 0.0001, respectively. Good neurological outcome after 180 days, assessed as a CPC score of 1-2, was found in 39 % versus 55%, p < 0.0001 and a modified Ranking Scale score of 0-3 was found in 39% versus 57%, p < 0.0001 in the high and low vasopressor group, respectively. The effect on neurological outcome of vasopressor group after 180 days did not differ between TTM groups for CPC (p interaction = 0.76) or modified Rankin Scale (p interaction = 0.64). Mortality and neurological outcome according to cardiovascular SOFA score during intervention stratified by TTM group is shown in Table 5 .
DISCUSSION
In this post hoc analysis of the TTM trial in post-cardiac arrest patients, we found that 1) the use of a target temperature of 33°C compared with 36°C is associated with decreased HR, elevated lactate levels and need for increased doses of vasopressors; 2) the requirement of high doses of vasopressors was an independent predictor of 30-day mortality adjusted for target temperature, demographics, and prehospital risk factors; 3) low MAP (< 65 mm Hg) during the intervention period was associated with increased mortality independent of level of vasopressor support 
PCAS and Hemodynamic Implication of Target
Temperature PCAS is a complex combination of several pathophysiological processes that include progressive brain injury, myocardial dysfunction, and systemic ischemia/reperfusion injury (1, 17) . The severity of the different components in PCAS may vary between patients but are in general thought to be related to prehospital cardiac arrest factors, with time to ROSC being a key determinant (1, 17) . We confirmed that prehospital factors as age, bystander cardiopulmonary resuscitation, time to ROSC, and initial lactate were all independent predictors of need for large doses of vasopressors, which could imply that the cardiovascular SOFA score describes the severity of PCAS. However, our analysis suggested that the prognostic importance of vasopressor support during treatment decreased when the hemodynamic derangements including lactate at hospital arrival were included in the model. Level of lactate is a strong predictor of outcome and significantly influenced the prognostic value of vasopressor support. High levels of lactate is a marker of the duration of the ischemic event, and furthermore we found lactate to be predictive of need for high doses of vasopressors. Therefore, patients with high levels of lactate and need for increased vasopressor support may represent patients with greater illness severity and thus increased risk of dying. Crude mortality rates indicated that need for high doses of vasopressors was associated with higher mortality in the TTM33 group when compared with that in the TTM36 group, but the difference in mortality was not statistically significant. TTM is applied as part of the management following OHCA aiming to prevent further evolution of PCAS and brain injury because lowering core temperature decreases oxygen consumption, cell metabolism, and inhibits apoptotic pathways (18) (19) (20) . However, TTM33 was associated with elevated levels of lactate, which may reflect inadequate peripheral perfusion because of vasoconstriction or lower lactate clearance. Vasoactive agents are often needed to improve myocardial performance, to counteract vasodilation, and to maintain adequate organ perfusion but may also cause tissue ischemia as an adverse event. Elevated levels of lactate may be a metabolic effect of the vasopressors administered, but data regarding the specific vasoactive agents administered were not available (21) . The biological effects of vasopressors, sedatives, and analgetics may be altered by lowering temperature because of changes in pharmacokinetics (22) (23) (24) . Furthermore, the choice of sedatives and analgetics used during hypothermia may have an independent effect on level of vasopressor support (25) .
Targeting MAP During Intervention
During target temperature intervention, MAP was not consistently different between TTM groups and MAP was higher than recommend by guidelines. However, MAP was slightly lower in TTM33 in the rewarming phase despite a greater positive fluid balance. This may be explained by temperature-related vasodilatation with shifts in volume distribution between compartments. Other studies suggest that targeting a positive fluid balance is important both during active cooling because of the phenomenon of "cold diuresis" and to counteract development of hypotension because of vasodilation during the rewarming phase when normal core temperature is restored (26, 27) .
In the present study, low mean MAP during the intervention was associated with increased risk of dying. Because of the observational nature of the present post hoc study, a clear inference for defining optimal target MAP during and after temperature management cannot be determined. However, current guidelines suggest a minimum of 65 mm Hg as a treatment goal for MAP during hypothermia, and our analysis seems to support this target because mortality risk increases below this level (Fig. 4) (28) . A recent study not only reported lower MAP values in vasopressor-dependent patients with adverse outcome when compared with patients with good outcome but also found that high values of MAP per se was not associated with good outcome (29) . Although a certain level of MAP is necessary to maintain organ perfusion, achieving a specific level of MAP may not be sufficient for increasing likelihood of survival. This suggests that targeting a higher level of MAP during intervention may not be translated into improved survival, but the impact of different targets of MAP could be addressed in future randomized clinical trials. It remains unproven which target MAP that may be optimal and it remains unproven whether it is the level of MAP per se or the effect of needing high vasoactive support that is most detrimental. Individual treatment goals of MAP with focus on close monitoring of adequate organ perfusion may be considered 
Limitations
First, our findings were based on an OHCA population with a clear indication for TTM as indicated by current guidelines. Patients suffering OHCA from noncardiac causes of cardiac arrest and patients presenting with a severe shock refractory to treatment after OHCA were excluded, and the findings of this study cannot be extrapolated to these patients. Second, no data on possible causes of low MAP and why MAP remained low despite use of vasopressors were available for the present study. Third, the lack of a standardized protocol for hemodynamic management during the intervention phase may also be considered a limitation. However, the present analysis is based on a pragmatic trial and thus generalizability should be high.
CONCLUSIONS
Targeted temperature management at 33°C was associated with decreased HR, elevated lactate levels, and increased need for vasopressor support compared with 36°C. Requirement for high doses of vasopressors and low MAP was both associated with increased 30-day mortality independent of allocated target temperature. Cardiovascular dysfunction as part of PCAS may have important implications for outcome, and future trials investigating the prognostic importance of different levels of MAP in the post-cardiac arrest period are needed to optimize targets for MAP. 
